Objective: To analyze serum metabonome of patients with breast carcinoma by gas chromatography-mass spectrometry (GC-MS).
Methods: Serum samples from 30 patients with breast carcinoma and 25 normal people were collected. Endogenous metabolites amino acids, fatty acids, saccharides and organic acids were analyzed after derivatization.
Result: The injection precision and intra-day precision (RSD) were less than 14.4 %. The method displayed good recovery (80.7 %-118.0 % with RSD<12.0 %) and linearity (r(2)>0.9905). Samples were stable in 24 h at room temperature. The samples were stable through three freeze-thaw cycles (RSD<14.6 %). Alaine,oxalate and glutamine were found with frequency of 96.7 %, 100 % and 93.3 %, respectively, which indicated that they may be the potential biomarkers.
Conclusion: The method is stable and reliable, which may be helpful for the diagnosis of breast cancer as an auxiliary method.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3785/j.issn.1008-9292.2009.05.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dynamic ultrasound-based modeling predictive of response to neoadjuvant chemotherapy in patients with early breast cancer.
Sci Rep
December 2024
Department of Breast Surgery, Second Affiliated Hospital of Dalian Medical University, No. 467 Zhongshan Road, Shahekou District, Dalian, China.
Early prediction of patient responses to neoadjuvant chemotherapy (NACT) is essential for the precision treatment of early breast cancer (EBC). Therefore, this study aims to noninvasively and early predict pathological complete response (pCR). We used dynamic ultrasound (US) imaging changes acquired during NACT, along with clinicopathological features, to create a nomogram and construct a machine learning model.
View Article and Find Full Text PDFMetaplastic breast cancer (MpBC) is a highly chemoresistant subtype of breast cancer with no standardized therapy options. A clinical study in anthracycline-refractory MpBC patients suggested that nitric oxide synthase (NOS) inhibitor NG-monomethyl-l-arginine (L-NMMA) may augment anti-tumor efficacy of taxane. We report that NOS blockade potentiated response of human MpBC cell lines and tumors to phosphoinositide 3-kinase (PI3K) inhibitor alpelisib and taxane.
View Article and Find Full Text PDFthe evolution of axillary management in breast cancer has witnessed significant changes in recent decades, leading to an overall reduction in surgical interventions. There have been notable shifts in practice, aiming to minimize morbidity while maintaining oncologic outcomes and accurate staging for newly diagnosed breast cancer patients. These advancements have been facilitated by the improved efficacy of adjuvant therapies.
View Article and Find Full Text PDFthe axillary reverse mapping (ARM) procedure aims to preserve the lymphatic drainage structures of the upper extremity during axillary surgery for breast cancer, thereby reducing the risk of lymphedema in the upper limb. Material and this prospective study included 57 patients with breast cancer who underwent SLNB and ARM. The sentinel lymph node (SLN) was identified using a radioactive tracer.
View Article and Find Full Text PDFCombined Autologous Breast Reconstruction and Gynecologic Procedures: Does Timing Affect Clinical and Patient-Reported Outcomes?
J Surg Oncol
December 2024
Section of Plastic and Reconstructive Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: Patients with or at risk for breast cancer may opt for risk-reducing gynecologic surgeries, including bilateral salpingo-oophorectomies and/or total abdominal hysterectomy. The timing and safety of combining these procedures with autologous breast reconstruction (ABR) are debated. This study assesses the impact of concurrent ABR and gynecologic surgeries on clinical and patient-reported outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!